Pulmonary embolism: new treatments for an old problem

Area of Science:

• Cardiology
• Pharmacology
• Emergency Medicine

Background:

• Acute pulmonary embolism (PE) presents a significant challenge for emergency departments, necessitating efficient diagnostic and risk assessment strategies.
• Nonvitamin K antagonist oral anticoagulants (NOACs) are increasingly recognized as viable treatment options for acute PE.
• Despite regulatory approval of agents like rivaroxaban, apixaban, dabigatran, and edoxaban, a degree of physician hesitancy persists regarding their adoption over conventional heparin/vitamin K antagonist therapies.

Approach:

• This review examines current clinical guidelines for anticoagulation in acute PE management within emergency settings.
• It analyzes the advantages of NOACs, specifically rivaroxaban and apixaban, highlighting their potential for single-drug therapy, cost-effectiveness, and simplified administration.
• The review further explores the underlying reasons contributing to the slow transition from established treatments to these newer oral anticoagulants.

Key Points:

• NOACs present a convenient and cost-effective single-drug approach for acute PE treatment.
• Simplified administration and management of NOACs may facilitate earlier patient discharge and outpatient care for low-risk individuals.
• The adoption of NOACs can potentially reduce the strain on emergency care infrastructures.

Conclusions:

• The transition to NOACs for acute PE management is slower than anticipated, despite their demonstrated benefits.
• Addressing physician reluctance and optimizing integration into emergency care pathways are crucial for wider adoption.
• Further research and education may be necessary to fully leverage the advantages of NOACs in acute PE treatment.